Tagged with Association,

association The CEO of NAPM reveals how the main challenge facing his members is the length of time needed to register a generic product, taking up to four years and acting as a significant block on investment, discusses the benefits that come with being part of the International Generic Pharmaceutical Alliance…

association The secretary general of the innovators’ association gives an overview of the current structural challenges facing the pharmaceutical industry in Turkey, and discusses the changes that need to be introduced for the vast potential of the Turkish pharmaceutical industry to be unlocked.   Could you give our readers a brief…

association The chairman of the British Chamber of Commerce in Turkey, the second oldest foreign British chamber in the world, discusses their efforts to increase investment in high value added services in Turkey, particularly R&D, and the domestic production of innovative products. As the the second-oldest British chamber in the world,…

association The CEO of Morocco’s oldest pharma association discusses the latest regulatory changes in Morocco and their impact on its members, as well as the position of Moroccan pharma in the African and European context. You have significant experience in the pharmaceutical industry in Morocco. What have been the key steps…

association Fatma Taman, Chair of ISPE and General Manager of PharmaVision, discusses the importance of proper education and training within the pharmaceutical industry to ensure the sector’s sustainable growth and development. Today we meet with you for the first time as the Chair of ISPE Turkey Affiliate; what have been your…

association The president of Turkey’s oldest pharmaceutical industry association discusses the government’s reluctance to reform the pricing system, and how this is causing the absorption of the domestic Turkish pharmaceutical industry by global big pharma. Turkey has traditionally been a branded generic market; how are these players performing at present? Roughly…

Romania The association’s longtime executive director outlines the opportunities and challenges for generics companies in the Romanian market. Analyzing in depth the local market regulatory landscape, he proposes modifications to the claw-back mechanism.   A non-governmental organization that aims to foster improved the access to affordable medicine for Romanian patients, The…

generics  Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth in the future.   You are currently the Vice President of CAPGEN; could you please tell us a bit about…

association The American Chamber of Commerce in Korea (Amcham Korea) was established in 1953 and has a long history in developing bilateral economic and trade relations between the US and Korea. Amy Jackson, president of the Chamber, discusses the implementation and effects of the Korea-US Free Trade Agreement (FTA) and the contributions…

pricing Cho Chan-Hwui, president of the Korean Pharmaceutical Association (KPA), discusses the major hurdles that pharmacists in Korea must overcome today, and the increased focus on prescription by INN.   How successfully has the policy stipulating the separation of prescription and dispensing (SPD) worked over the last 15 years? Complete success…

association On behalf of the chamber of industry that represents research-based pharma and biopharma companies in Argentina, Ernesto Felicio discusses the current challenges facing the industry, and the chambers current agenda for change.   To what extent has the environment for multinationals, or their role in the Argentinian pharmaceutical industry, significantly…

association Elmer Torres Cortes is General Manager of the Industrial Association of Pharmaceutical Laboratories (ASILFA) that was created to defend the interests of the generic and local manufacturers. Cortes speaks about the developments of the Chilean pharmaceutical industry.   What are the main drivers and challenges for the Chilean pharmaceutical industry…